Samfundsansvar

Medier: COVID-vacciner markant mindre effektive tre månender efter 2. stik

Morten W. Langer

torsdag 19. august 2021 kl. 23:12

Uddrag fra Zerohedge/ Bloomberg/

The largest study yet to examine the efficacy of COVID vaccines in the wild has just been published by the University of Oxford and UK Office for National Statistics, and unsurprisingly it found that the efficacy rates for the Pfizer and Moderna are significantly lower than the 90%+ rates first advertised from the initial controlled trials.

According to the study, a preprint of which was published on Thursday, while the Pfizer, Moderna and AstraZeneca jabs still offer “good” protection against new infections, their efficacy has been reduced compared with Alpha. While having two doses of either vaccine still provides “at least the same level of protection as having had COVID-19”, those who were vaccinated after already being infected demonstrated even higher levels of protection than those who either weren’t infected and only received the jabs, or were infected, but didn’t receive the jabs.

 “We’re seeing here the real-world data of how two vaccines are performing, rather than clinical trial data, and the data sets all show how the delta variant has blunted the effectiveness of both the Pfizer and AstraZeneca jabs,” said Simon Clarke, an associate professor in cellular microbiology at the University of Reading.

Despite all this, even after receiving two doses of a jab, those infected with delta showed much higher peak levels of the virus than those infected with alpha, or some other variant.

The study also highlighted differences between between vaccines: for example, the Moderna jab had “similar or greater effectiveness” against the delta variant as a single dose of the other vaccines. And while the Pfizer and Moderna jabs showed greater initial efficacy against infection than the AstraZeneca jab, this protection premium erodes after only 4-5 months.

Source: Bloomberg

The data also showed that delta increases transmissibility more than other COVID varients, even among the vaccinated, which backs up a recent assessment made by the American CDC.

The results raise more doubt about the possibility of ever achieving herd immunity via vaccination, said Sarah Walker, a professor of medical statistics and epidemiology at Oxford, who helped lead the study. That’s not exactly a surprise.

Finally, one important piece of the puzzle that’s still missing is the data relating to hospitalizations and severe cases of COVID, according to Penny Ward, a visiting professor in pharmaceutical medicine at King’s College London, who wasn’t involved with the study, and spoke to Bloomberg about its results. It’s possible the findings could support “cross-vaccination” with different types of jabs, which could offer more comprehensive protection, she said.

Del på facebook
Del på twitter
Del på linkedin
Del på email
Del på print

[postviewcount]

Jobannoncer

Afdelingsleder til nøglerolle inden for økonomistyring i Vejdirektoratet
Wonderful Copenhagen søger en dygtig business controller
Finanstilsynet søger Teamleder til kontor på kapitalmarkedsområdet – prospektområdet
Nysgerrig kollega søges til tilsyn med pengeinstitutter
Pensam søger udviklingsorienteret økonom til product management
Direktør for Job og Økonomi Favrskov Kommune
Dansk Energi søger konsulent til at arbejde med den grønne omstilling
International shipping company seeks ambitious Group Financial Controller
Økonom søges til EjendomDanmark
Plesner søger økonom til Team EU & Competition
Finansiel Stabilitet søger ny kollega til afdelingen Kredit og Interne Advokater
Finansiel Stabilitet søger dygtig og engageret økonom
To dygtige akademikere søges til spændende økonomiopgaver vedrørende de videregående uddannelsesinstitutioner
Senior Financial Controller til Sparekassen Sjælland-Fyn
Socialtilsyn Syd søger en konsulent med stærk økonomisk forståelse
Student til Forhandlingsafdelingen i Dansk Sygeplejeråd
Ergoterapeutforeningen søger teamleder til økonomi
Regnskabschef i Uddannelses- og Forskningsstyrelsen
Ny kollega til stærkt regnskabsteam i Uddannelses- og Forskningsstyrelsen
Nationalbanken søger sektionschef for international økonomi, relationer & strategi
Business analyst til myndighedsrapporterings-teamet
Energinet søger Finansiel Business Partner til Koncernøkonomi
Udviklingsorienteret talknuser til håndtering af driftsbudgetter for det danske el-net
Professionel leder med strategisk overblik og økonomisk indsigt
Kalundborg Kommune søger Teamleder til Team løn, ejendomsskat og opkrævning (LEO)

Mere fra ØU Samfundsansvar

Seneste nyt

Mest læste

Få dit daglige nyhedsoverblik i din indbakke

Seneste rapporter fra eksterne rådgivere

Dybdegående og original 
journalistik siden 1994

Økonomisk Ugebrev har i mere end 25 år leveret indsigtsfuld og dagsordensættende journalistik og analyser til læserne og den brede offentlighed. 

Vi tager ansvar for vores indhold og er tilmeldt:

OM ØU

Log ind

KONTAKT

Telefonisk henvendelse: 70 23 40 10
Telefonerne er åbne alle hverdage fra: 10-15
Salgschef: Sidsel Bogh

Skriv til os på: kontakt@ugebrev.dk.
Vi bestræber os på at besvare henvendelser indenfor 24 timer.

Økonomisk Ugebrev A/S
CVR-nr.: 31760623
Forbindelsesvej 12, 2. tv
2100 København Ø

Log ind

Har du ikke allerede en bruger? Opret dig her.

Analyse af og prognoser for Fixed Income (statsrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank

 

Log ind

[iteras-paywall-login paywallid="qwerty123"]